Thermo Fisher Scientific Inc. $TMO Shares Sold by Banque Pictet & Cie SA

Key Points

• Banque Pictet & Cie SA reduced its holdings in Thermo Fisher Scientific by 52.7%, now owning 31,856 shares valued at approximately $12.9 million.
• The company reported $5.36 earnings per share for the last quarter, exceeding analyst expectations, and has set Q3 2025 guidance at 5.460-5.510 EPS.
• The dividend of $0.43 per share will be paid on October 15th, representing an annual yield of 0.4%.

Banque Pictet & Cie SA reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 52.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,856 shares of the medical research company's stock after selling 35,469 shares during the quarter. Banque Pictet & Cie SA's holdings in Thermo Fisher Scientific were worth $12,916,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $30,000. Park Square Financial Group LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $49,000. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Thermo Fisher Scientific by 1.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 127,272 shares of the medical research company's stock worth $66,211,000 after acquiring an additional 1,556 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 1.9%

Shares of TMO opened at $459.34 on Friday. The company has a market capitalization of $173.45 billion, a P/E ratio of 26.57, a P/E/G ratio of 2.54 and a beta of 0.75. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a 50-day moving average price of $475.73 and a 200 day moving average price of $448.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TMO shares. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Barclays raised Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.